Literature DB >> 1907999

Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.

N P Restifo1, F Esquivel, A L Asher, H Stötter, R J Barth, J R Bennink, J J Mulé, J W Yewdell, S A Rosenberg.   

Abstract

MHC class I-restricted CTL play a central role in the immune response against methylcholanthrene (MCA)-induced sarcomas in mice. We, therefore, hypothesized that MCA-induced tumors may evade immune recognition by failing to present Ag to CD8+ CTL. Of a number of previously described MCA-induced sarcomas, one, MCA 101, fails to induce CTL, is nonimmunogenic, and grows rapidly and lethally in nonimmunosuppressed recipients. To better understand the nonimmunogenicity of MCA 101 we examined its ability to present foreign Ag to CTL. Unlike immunogenic sarcomas, MCA 101 failed to present endogenously synthesized influenza virus Ag to influenza virus-specific CTL. The deficiency in presentation of endogenous Ag by MCA 101 was attributed to a markedly reduced rate of synthesis of class I molecules because up-regulation of class I synthesis by IFN-gamma greatly increased the presentation of influenza A virus Ag. Despite low levels of cell surface class I expression, MCA 101 presented exogenous peptide Ag to anti-influenza CTL with efficiency similar to immunogenic MCA sarcoma cell lines. These findings could not be attributed to deficiencies in class I assembly or transport, as has been suggested by others who have studied mutant cells with defective Ag presentation. Furthermore, our studies suggest that some tumor cells can escape recognition by CTL and subsequent immune eradication by suppressing presentation of endogenous Ag.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907999      PMCID: PMC1950464     

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  45 in total

1.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

Authors:  G KLEIN; H O SJOGREN; E KLEIN; K E HELLSTROM
Journal:  Cancer Res       Date:  1960-12       Impact factor: 12.701

2.  Immunity to methylcholanthrene-induced sarcomas.

Authors:  R T PREHN; J M MAIN
Journal:  J Natl Cancer Inst       Date:  1957-06       Impact factor: 13.506

3.  Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters.

Authors:  J Trowsdale; I Hanson; I Mockridge; S Beck; A Townsend; A Kelly
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

4.  Role of different T cells sets in the rejection of syngeneic chemically induced tumors.

Authors:  K Shimizu; F W Shen
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

5.  H-2 restriction of adoptive immunotherapy of advanced tumors.

Authors:  P D Greenberg; M A Cheever; A Fefer
Journal:  J Immunol       Date:  1981-06       Impact factor: 5.422

6.  A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway.

Authors:  T Spies; M Bresnahan; S Bahram; D Arnold; G Blanck; E Mellins; D Pious; R DeMars
Journal:  Nature       Date:  1990 Dec 20-27       Impact factor: 49.962

7.  Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies.

Authors:  W Gerhard; J Yewdell; M E Frankel; R Webster
Journal:  Nature       Date:  1981-04-23       Impact factor: 49.962

8.  Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

Authors:  K Kärre; H G Ljunggren; G Piontek; R Kiessling
Journal:  Nature       Date:  1986 Feb 20-26       Impact factor: 49.962

9.  Monoclonal antibodies to mouse MHC antigens. III. Hybridoma antibodies reacting to antigens of the H-2b haplotype reveal genetic control of isotype expression.

Authors:  K Ozato; D H Sachs
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

10.  Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism.

Authors:  H G Ljunggren; K Kärre
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  26 in total

1.  Differences in the level of expression of class I major histocompatibility complex proteins on thymic epithelial and dendritic cells influence the decision of immature thymocytes between positive and negative selection.

Authors:  J R Delaney; Y Sykulev; H N Eisen; S Tonegawa
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 2.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

Review 3.  Enhancing the recognition of tumour associated antigens.

Authors:  N P Restifo; B R Minev; A S Taggarse; B J McFarland; M Wang; K R Irvine
Journal:  Folia Biol (Praha)       Date:  1994       Impact factor: 0.906

4.  Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.

Authors:  T D Schell; L M Mylin; I Georgoff; A K Teresky; A J Levine; S S Tevethia
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 5.  Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.

Authors:  N P Restifo; Y Kawakami; F Marincola; P Shamamian; A Taggarse; F Esquivel; S A Rosenberg
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1993-10

6.  Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.

Authors:  E Shiloni; S E Karp; M C Custer; J Shilyansky; N P Restifo; S A Rosenberg; J J Mulé
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

7.  Genetic susceptibility to type 1 diabetes in the intracellular pathway of antigen processing - a subject review and cross-study comparison.

Authors:  Charles Sia; Michael Weinem
Journal:  Rev Diabet Stud       Date:  2005-05-10

8.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; T B Simonis; A Abati; J Hackett; T O'Dea; P Fetsch; J Yannelli; N P Restifo; J J Mulé
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-07

9.  Characterization of defectiveness in endogenous antigen presentation of novel murine cells established from methylcholanthrene-induced fibrosarcomas.

Authors:  K Kuroda; K Yamashina; N Kitatani; A Kagishima; T Hamaoka; Y Hosaka
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

10.  Antigen processing in vivo and the elicitation of primary CTL responses.

Authors:  N P Restifo; I Bacík; K R Irvine; J W Yewdell; B J McCabe; R W Anderson; L C Eisenlohr; S A Rosenberg; J R Bennink
Journal:  J Immunol       Date:  1995-05-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.